AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2673590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin plus M. leprae soluble antigens
Number of subjects: 213
Study 2673590 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin alone
Number of subjects: 213
Study 1190686 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 10 mg/kg intravenously at 8-hour intervals for three doses
Number of subjects: 45
Study 1190686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 45
Study 30216527 — intervention group
Group type: EXPERIMENTAL
Intervention: High nickel-releasing metal discs for 10, 30 and 60 minutes on 3 occasions over a period of 2 weeks
Number of subjects: 45
Study 30216527 — intervention group
Group type: EXPERIMENTAL
Intervention: High nickel-releasing metal discs for repetitive exposures of up to 30 minutes on 3 occasions over a period of 2 weeks
Number of subjects: 45
Study 27515930 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-wide health education program and availability of salt substitute at village shops
Number of subjects: 1903
Study 27515930 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1903
Study 27515930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1903
Study 25267131 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered care program (routine hospital services plus a family-centered care program consisting of need assessment, educating families based on patients' needs, follow-ups by short phone interviews, and referral service)
Number of subjects: 60
Study 25267131 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital services (control group)
Number of subjects: 60
Study 22334056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (50 minutes, four times weekly for 24 weeks)
Number of subjects: 176
Study 22334056 — intervention group
Group type: COMPARATOR
Intervention: Control group (health lectures twice a month)
Number of subjects: 176
Study 20639391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hypertension
Number of subjects: 43
Study 18549492 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care interventions (three step treatment approach: step 1 - behavioural change counselling, step 2 - three sessions of motivational enhancement therapy, step 3 - referral to specialist services)
Number of subjects: 0
Study 18549492 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 0
Study 16156456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 100
Study 16156456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12610040 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine prebedtime plus lispro preprandially (LIS/GLAR)
Number of subjects: 28
Study 12610040 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin prebedtime plus regular human insulin preprandially (R/NPH)
Number of subjects: 28
Study 10369072 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy
Number of subjects: 0
Study 7577201 — intervention group
Group type: EXPERIMENTAL
Intervention: Less extensive treatment
Number of subjects: 0
Study 7577201 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 1882110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 7
Study 1882110 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-lying position
Number of subjects: 7
Study 7032533 — intervention group
Group type: EXPERIMENTAL
Intervention: plafibride
Number of subjects: 30
Study 31932201 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement 2000 IU per day for 2 months
Number of subjects: 149
Study 31932201 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 149
Study 29251686 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 24
Study 29251686 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 26988095 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs on inhalation techniques (one session with a monitor)
Number of subjects: 267
Study 25038522 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP+PAV
Number of subjects: 0
Study 25038522 — intervention group
Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 0
Study 22454251 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10 mg BID)
Number of subjects: 440
Study 22454251 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10 or 20 mg QD)
Number of subjects: 440
Study 20446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sTNFR-1
Number of subjects: 0
Study 20446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sCD27
Number of subjects: 0
Study 20446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of sCD40L
Number of subjects: 0
Study 20446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment concentrations of plasma IL-6
Number of subjects: 0
Study 20446847 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR-1, sCD27, and sCD40L
Number of subjects: 0
Study 18021264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 1 g, 1 h pre-operatively and 2 g for 2 days post-operatively (Antibiotics group)
Number of subjects: 80
Study 18021264 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Non-antibiotics group)
Number of subjects: 80
Study 15901755 — intervention group
Group type: EXPERIMENTAL
Intervention: SFR (known target location with random head direction)
Number of subjects: 6
Study 15901755 — intervention group
Group type: EXPERIMENTAL
Intervention: SFP (known target location with known head direction)
Number of subjects: 6
Study 15901755 — intervention group
Group type: COMPARATOR
Intervention: HF trials
Number of subjects: 6
Study 15901755 — intervention group
Group type: COMPARATOR
Intervention: SF trials
Number of subjects: 6
Study 15460663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake at 2100 hrs
Number of subjects: 0
Study 15460663 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 0
Study 10638381 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 20
Study 10638381 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 20
Study 10638381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowers
Number of subjects: 20
Study 10638381 — intervention group
Group type: COMPARATOR
Intervention: Nonathletes
Number of subjects: 20
Study 9197875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 17 beta‐oestradiol orally (2 mg daily)
Number of subjects: 140
Study 9197875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 17 beta‐oestradiol transdermally (50 micrograms daily)
Number of subjects: 140
Study 9197875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 140
Study 9197875 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 140
Study 1527230 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate or dextroamphetamine in individualized doses
Number of subjects: 7
Study 1527230 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate or dextroamphetamine
Number of subjects: 7
Study 3549870 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0
Study 3549870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0
Study 31036709 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (various brands)
Number of subjects: 449
Study 31036709 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicondylar constructs
Number of subjects: 449
Study 31036709 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (in men aged 55-75 years)
Number of subjects: 449
Study 31036709 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee replacement constructs (in women aged 55-75 years)
Number of subjects: 449
Study 31036709 — intervention group
Group type: COMPARATOR
Intervention: Contemporary benchmark construct
Number of subjects: 449
Study 29102524 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 612
Study 29102524 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMC
Number of subjects: 612
Study 29102524 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGA
Number of subjects: 612
Study 29102524 — intervention group
Group type: COMPARATOR
Intervention: Control (4L of PEG)
Number of subjects: 612
Study 26861923 — intervention group
Group type: EXPERIMENTAL
Intervention: High in monounsaturated fat (extra-virgin olive oil)
Number of subjects: 13
Study 26861923 — intervention group
Group type: COMPARATOR
Intervention: Low fat
Number of subjects: 13
Study 26861923 — intervention group
Group type: COMPARATOR
Intervention: High in saturated fat (butter)
Number of subjects: 13
Study 26861923 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index meals
Number of subjects: 13
Study 24944054 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Grains (WG)
Number of subjects: 50
Study 24944054 — intervention group
Group type: COMPARATOR
Intervention: Refined Grains (RG)
Number of subjects: 50
Study 23611825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU orally every 3 months for 4 doses)
Number of subjects: 52
Study 23611825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23611825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 52
Study 19926166 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antibiotics
Number of subjects: 0
Study 19926166 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics unless clinically indicated)
Number of subjects: 0
Study 18833105 — intervention group
Group type: EXPERIMENTAL
Intervention: Rileptid (generic risperidone)
Number of subjects: 0
Study 18833105 — intervention group
Group type: COMPARATOR
Intervention: Rispolept (original risperidone)
Number of subjects: 0
Study 16616748 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal-phase acupuncture
Number of subjects: 225
Study 16616748 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 225
Study 14652885 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine
Number of subjects: 183
Study 14652885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 183
Study 14652885 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 183
Study 11095136 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA)
Number of subjects: 70
Study 11095136 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 70
Study 8621005 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 17
Study 8621005 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrates (CHOs)
Number of subjects: 17
Study 1582188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (non-selective beta-blocker with moderate intrinsic sympathomimetic activity), given by the Oros delivery system
Number of subjects: 0
Study 1582188 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-selective blocker without ISA)
Number of subjects: 0
Study 1582188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30909333 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 212
Study 30909333 — intervention group
Group type: COMPARATOR
Intervention: HP plus TAZ
Number of subjects: 212
Study 28525401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 72
Study 28525401 — intervention group
Group type: COMPARATOR
Intervention: Airtraq
Number of subjects: 72
Study 25924860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team-based (ITB) learning
Number of subjects: 29
Study 25924860 — intervention group
Group type: COMPARATOR
Intervention: Individual discipline-based (DB) learning
Number of subjects: 29
Study 23536963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of black pepper essential oil for 2 minutes
Number of subjects: 20
Study 23536963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of angelica essential oil for 2 minutes
Number of subjects: 20
Study 21300083 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace POWER program (n=65)
Number of subjects: 110
Study 21300083 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=45)
Number of subjects: 110
Study 19583067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 82
Study 17456491 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.42
Number of subjects: 50
Study 17456491 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 50
Study 15161771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (P+) 45 mg for 21 days
Number of subjects: 9
Study 15161771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-)
Number of subjects: 9
Study 12101864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg or 600 mg) and Misoprostol (400 micrograms)
Number of subjects: 80
Study 12101864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg or 600 mg) and Misoprostol (600 micrograms)
Number of subjects: 80
Study 12101864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg and Misoprostol (400 micrograms)
Number of subjects: 80
Study 9867054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0
Study 9867054 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis and randomization concerns
Number of subjects: 0
Study 9867054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical benefits of steroids
Number of subjects: 0
Study 9867054 — intervention group
Group type: EXPERIMENTAL
Intervention: Risks of intervention
Number of subjects: 0
Study 8079827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 91
Study 8079827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 2536867 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: eight courses of cyclophosphamide, doxorubicin, and vincristine
Number of subjects: 112
Study 2536867 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: two courses of three sequential drug combinations (1) cyclophosphamide, lomustine, and methotrexate; (2) cyclophosphamide, doxorubicin, and vincristine; (3) ifosfamid and etoposide
Number of subjects: 112
Study 4465285 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygotes identified in families of Libyan origin
Number of subjects: 24
Study 4465285 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly screened healthy school children of Libyan origin
Number of subjects: 24
Study 4465285 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined cystine urolithiasis frequency
Number of subjects: 24
Study 30332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation + mastery learning
Number of subjects: 264
Study 30332904 — intervention group
Group type: COMPARATOR
Intervention: Simulation without mastery learning (Control)
Number of subjects: 264
Study 28839341 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (NBI-98854)
Number of subjects: 430
Study 25732417 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA + Bezafibrate (BF)
Number of subjects: 27
Study 25732417 — intervention group
Group type: COMPARATOR
Intervention: UDCA monotherapy
Number of subjects: 27
Study 24308450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15212
Study 24308450 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 15212
Study 24308450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (excluding patients who died)
Number of subjects: 15212
Study 24308450 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (excluding patients who died)
Number of subjects: 15212
Study 21355914 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 82
Study 21355914 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 82
Study 19067726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 20
Study 19067726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17224756 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 153
Study 17224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation resonance tonometry (ARTBiom)
Number of subjects: 153
Study 17224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation resonance tonometry (ARTHand)
Number of subjects: 153
Study 17224756 — intervention group
Group type: COMPARATOR
Intervention: Measurement order (first vs last method)
Number of subjects: 153
Study 15142013 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training routine (3 sets of 8‐10 repetitions at 75% of 1 repetition maximum) of 8 large muscle mass exercises using resistance machines
Number of subjects: 16
Study 15142013 — intervention group
Group type: COMPARATOR
Intervention: Control group (sat quietly in the training facility)
Number of subjects: 16
Study 11903412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control (IC)
Number of subjects: 43
Study 11903412 — intervention group
Group type: COMPARATOR
Intervention: Usual glycaemic control (UC)
Number of subjects: 43
Study 9388412 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassiodol (iodised rapeseed oil) at a dose of 2 mL
Number of subjects: 0
Study 9388412 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol (poppyseed-based iodised oil)
Number of subjects: 0
Study 7532743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with elevated S/P ratio
Number of subjects: 718
Study 7532743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with microalbuminuria
Number of subjects: 718
Study 7532743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with long duration of disease
Number of subjects: 718
Study 7532743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 718
Study 3279725 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 27
Study 3279725 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. with moderate dietary salt reduction
Number of subjects: 27
Study 3279725 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. with hydrochlorothiazide 25 mg daily
Number of subjects: 27
Study 3279725 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 27
Study 31208916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening exercises
Number of subjects: 105
Study 31208916 — intervention group
Group type: COMPARATOR
Intervention: General functional exercises
Number of subjects: 105
Study 28597253 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient education program provided by specially trained oncology nurses
Number of subjects: 165
Study 28597253 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual oncologist counseling)
Number of subjects: 165
Study 25911546 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 2 hours after mifepristone
Number of subjects: 100
Study 25911546 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 48 hours after mifepristone
Number of subjects: 100
Study 23406684 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day home blood pressure monitoring (HBPM) protocol
Number of subjects: 158
Study 23406684 — intervention group
Group type: COMPARATOR
Intervention: 5-day home blood pressure monitoring (HBPM) protocol
Number of subjects: 158
Study 21346616 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 60
Study 21346616 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 1200 mg/d
Number of subjects: 60
Study 19858437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (NCM and CHW team)
Number of subjects: 542
Study 19858437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (NCM and CHW team) with most visits
Number of subjects: 542
Study 19858437 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (mailings and telephone calls)
Number of subjects: 542
Study 17581217 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg/day, p.o.)
Number of subjects: 0
Study 17581217 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects with premature ventricular beats, no structural heart disease)
Number of subjects: 0
Study 17581217 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM (untreated)
Number of subjects: 0
Study 15699266 — intervention group
Group type: EXPERIMENTAL
Intervention: avasimibe 750 mg QDS for 8 weeks
Number of subjects: 21
Study 11984291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week wheelchair practice period on a computer-controlled wheelchair ergometer
Number of subjects: 20
Study 11984291 — intervention group
Group type: COMPARATOR
Intervention: Control group (only participated in trials 1 and 9)
Number of subjects: 20
Study 10544534 — intervention group
Group type: EXPERIMENTAL
Intervention: nasally administered continuous positive airway pressure (CPAP) therapy
Number of subjects: 0
Study 10544534 — intervention group
Group type: EXPERIMENTAL
Intervention: recent technological developments in CPAP therapy
Number of subjects: 0
Study 10544534 — intervention group
Group type: EXPERIMENTAL
Intervention: semiattended and unattended settings for CPAP therapy
Number of subjects: 0
Study 8553353 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (Doppler) observation
Number of subjects: 55
Study 2272957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone and pyruvate (DHAP) supplementation
Number of subjects: 8